Sanofi said earlier this year that it would focus development in diabetes, cancer and ophthamology. Yesterday they announced two new deals in the diabetes and ophthamology areas. Sanofi will team with Columbia University Medical Center on new diabetes treatments. These will be based on the osteoblast-secreted peptide, osteocalcin. Osteocalcin helps regulate osteoblasts which produce a hormone that regulates blood sugar levels and fat deposition. The deal is for three years.
The second deal is between Sanofi and Europe's Vision Institute to gain access to its technology platforms to study vascular biology, inflammation, gene therapy and optic nerve regeneration. Sanofi will have rights to any treatments discovered in the collaboration. See Fierce Biotech.
Posted by Bruce Lehr March 26th 2011.